NVOS Novo Integrated Sciences Corp: Forward Price-to-Revenue Multiple

Public company logo of Novo Integrated Sciences Inc (NVOS)

Entry into the business is restricted by strict HIPAA oversight and licensing, yet it is protected by IT integration. The forward P/S metric illustrates the valuation trend, where the value of 0.20 reflects this status. Novo Integrated Sciences (NVOS) generates revenue from patient diagnostics and treatment in the US and Canada. A lack of pricing power forces the company to compete via discounts due to the high elasticity of demand for medical services.

Novo Integrated Sciences, Inc. - NVOS Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/16/2024)

Analytical breakdowns for Novo Integrated Sciences (NVOS)

- market price and analyst price targets:
Initial company analysis:Novo Integrated Sciences Inc NVOS
Manufactured products of Novo Integrated Sciences Corp

This indicator reflects the ratio of the market value of Novo Integrated Sciences (NVOS) to projected revenue, allowing for an assessment of the premium paid for future income streams. By analyzing the firm's forward P/S, an investor can weigh market expectations against client base volatility risks and SEC regulatory pressure, which determines the long-term sustainability of the business valuation amid unstable financing for large-scale deals.

Main competitors

Forward P/S Multiple HCA (HCA Healthcare, Inc.)|Price to Expected Revenue Ratio THC (Tenet Healthcare)|FMS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solventum.com|EHC: Forward P/S Multiple|UHS - Market Cap to Expected Sales Ratio|DVA (DaVita Corp) - Forward P/S Multiple|RDNT: Forward Price to Sales|Forward P/S Multiple OPCH|SGRY (surgerypartners.com) - Forward Price to Sales|Forward P/S Multiple PINC (Premier Inc)|National Vision - Price-to-Projected Revenue Ratio|PGNY - Price-to-Projected Revenue Ratio|ARDT - Forward P/S Multiple|SEM: Forward P/S Multiple|astranahealth.com (ASTH) - Forward P/S Multiple|MD (mednax.com) - Forward P/S Multiple|Forward P/S Multiple usph.com|Forward P/S Multiple PNTG|Market Cap to Expected Sales Ratio Organogenesis Holdings|Forward P/S Multiple NUTX (nutexhealth.com)|Auna SA (AUNA) - Market Cap to Future Revenue Ratio|SBC: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Jeuveau EOLS|CYH (Community Health Systems Inc) - Forward Price-to-Revenue Multiple|SKIN: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple MDWD|BTMD: Forward Price to Sales|Price-to-Projected Revenue Ratio The Joint Corporation (JYNT)|Forward P/S Multiple DocGo Inc (DCGO)|Forward Price to Sales P3 Health Partners, Inc.|Market Cap to Expected Sales Ratio gaintherapeutics.com (GANX)|EUDA: Forward Price-to-Revenue Multiple|BMGL: Price-to-Projected Revenue Ratio|collplant.com (CLGN) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Cuprina Holdings|CCM (concordmedical.com) - Forward P/S Multiple|Forward P/S Multiple ASHS|Price-to-Projected Revenue Ratio MEDIROM (MRM)|ALBT - Market Cap to Future Revenue Ratio|DIH Holding US, Inc. - Forward Price-to-Revenue Multiple|Projected Price to Revenue Carmell Therapeutics Corporation|NewGenIvf Corp - Forward P/S Multiple|ATI Physical Therapy, Inc. - Price to Expected Revenue Ratio|CMAX: Forward P/S Multiple|Market Cap to Projected Revenue KDLY|Forward Price-to-Revenue Multiple MODV|Market Cap to Future Revenue Ratio SunLink Health Systems SSY|Price-to-Projected Revenue Ratio IMAC Corp (BACK)